LETTERS OF INTENT

Stand Up To Cancer (SU2C) calls upon members of the SU2C community to contribute ideas for clinical research to the California Institute of Regenerative Medicine’s (CIRM) CLIN 2 grant program.

CIRM and SU2C are working together to identify clinical trials that may qualify for support under the CIRM Clinical Trial Stage Projects CLIN 2 grant program( ). In addition to traditional stem cell research, CIRM would like to support projects that involve memory t-cells, progenitor cells (e.g. monocyte-derived dendritic cells), or treatments that target cancer stem cells as their primary mechanism of action. CIRM will fund portions of trials that are conducted in California, or trials that are led by a California-based lead investigator. Note that expansion of existing SU2C-affiliated clinical trials or design of new SU2C-affiliated clinical trials may qualify for this funding to support treatment of California patients under a California lead investigator / clinical trialist.

CIRM and SU2C invite you to submit a brief letter of intent before submitting a formal application. CIRM and SU2C will review the letter to ensure that the project is appropriate for this collaborative CLIN 2 program. In addition, CIRM staff has offered to provide feedback on draft applications in order to improve the likelihood that they would be approved. Once submitted, the applications will be subject to an independent peer review process, overseen by CIRM. Grant applications are considered on a rolling basis and you are free to apply directly to the program at any time, but we encourage you to take advantage of this process to maximize your chances of securing funding.

ELIGIBILITY CRITERIA

Eligibility criteria are listed in the Partnering Opportunity for Clinical Trial Stage Projects (CLIN 2) Program Announcement ( ). Candidates with a question about the eligibility requirements are encouraged to contact SU2C at prior to submitting the proposal.

IDEA SUBMISSION DEADLINE

The first round of letters must be emailed to by 5:00pm (ET) on July 8, 2016. After that date, SU2C and CIRM will review letters of intent on a monthly basis.

IDEA SUBMISSION INSTRUCTIONS

THE FOLLOWING INFORMATION IS REQUIRED TO SUBMIT A COMPLETE LETTER OF INTENT:

  • Scientific Abstract - Limited to 500 words, should provide a clear, concise overview of the proposed cancer research project.
  • Eligibility Confirmation – A brief statement affirming that the proposed project is eligible for funding by CIRM according to the requirements listed in the Partnering Opportunity for Clinical Trial Stage Projects (CLIN 2) Program Announcement ( ).
  • Submission – Format submission as a PDF or Microsoft Word document and submit to .

QUESTIONS?

E-mail (preferred):

I. Investigator CONTACT Information

Full Name:
Last (Family) / First (Given) / Middle Initial
Degree: / MD PhD MD, PhD PharmD Other:
Title/Position:
Department:
Institution:
Mailing Address:
City / State / Zip Code
Country:
Telephone:
E-mail:
Assistant’s Name
Assistant’s E-mail
II. IDEA SUBMISSION (LETTER OF INTENT)

Margins must be no less than 0.75 inches. Font size must be 12 point Times New Roman, and no smaller than 9 point type for figures, legends, and tables. Single-spacing is acceptable. Please use template provided (see next page).

  • Scientific Abstract – In 500 words or less,provide an overview of the proposed clinical research project including the project goals, indication(s), therapeutic approach, clinical trial phase, and scientific rationale.
  • Eligibility Confirmation – Please include a brief statement affirming that the proposed project is eligible for funding by CIRM according to the requirements listed in the Partnering Opportunity for Clinical Trial Stage Projects (CLIN 2) Program Announcement
  • Key Literature References – References to publications supporting the proposed research may be included and should not exceed more than one page. References must be listed as full citations.

Stand Up to Cancer / California Institute for Regenerative MedicinePage 1 of 5

Investigator Name (Last, first, middle):

LETTER OF INTENT

References (maximum one page):

Stand Up to Cancer / California Institute for Regenerative MedicinePage 1 of 5